{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:01:45Z","timestamp":1792440105081,"version":"4.5.0"},"reference-count":10,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Ribavirin is the only available Lassa fever treatment. The rationale for using ribavirin is based on one clinical study conducted in the early 1980s. However, reanalysis of previous unpublished data reveals that ribavirin may actually be harmful in some Lassa fever patients. An urgent reevaluation of ribavirin is therefore needed.<\/jats:p>","DOI":"10.1371\/journal.pntd.0009522","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T17:27:04Z","timestamp":1625765224000},"page":"e0009522","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":66,"title":["Time to reconsider the role of ribavirin in Lassa fever"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3139-3321","authenticated-orcid":true,"given":"Alex Paddy","family":"Salam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6162-4146","authenticated-orcid":true,"given":"Vincent","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6110-014X","authenticated-orcid":true,"given":"Tansy","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1426-3680","authenticated-orcid":true,"given":"Piero","family":"Olliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8496-6053","authenticated-orcid":true,"given":"Jonathan","family":"Sterne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-1586","authenticated-orcid":true,"given":"Peter","family":"Horby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"issue":"3","key":"pntd.0009522.ref001","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/infdis\/155.3.445","article-title":"A case-control study of the clinical diagnosis and course of Lassa fever","volume":"155","author":"JB McCormick","year":"1987","journal-title":"J Infect Dis"},{"issue":"20","key":"pntd.0009522.ref002","article-title":"Measures to control protracted large Lassa fever outbreak in Nigeria, 1 January to 28 April 2019","volume":"24","author":"CC Dan-Nwafor","year":"2019","journal-title":"Euro Surveill"},{"issue":"1","key":"pntd.0009522.ref003","first-page":"11693","volume":"7","author":"P Carrillo-Bustamante","year":"2017","journal-title":"Determining Ribavirin\u2019s"},{"issue":"9","key":"pntd.0009522.ref004","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3201\/eid2409.180233","article-title":"Use of Favipiravir to Treat Lassa Virus Infection in Macaques","volume":"24","author":"K Rosenke","year":"2018","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"pntd.0009522.ref005","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nm.4396","article-title":"Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever","volume":"23","author":"CE Mire","year":"2017","journal-title":"Nat Med"},{"issue":"1","key":"pntd.0009522.ref006","first-page":"20","article-title":"Lassa fever. Effective therapy with ribavirin","volume":"314","author":"JB McCormick","year":"1986","journal-title":"N Engl J Med"},{"key":"pntd.0009522.ref007","year":"1992","journal-title":"Birch & Davis Associates and Sherikon Inc. on behalf of the U.S. Army Medical Research and Development Command. Final Report Analysis of a Clinical Trial Ribavirin and the Treatment of Lassa Fever. Report No.: IND"},{"key":"pntd.0009522.ref008","author":"GV Ludwig","year":"2019","journal-title":"U.S. Freedom of Information Act"},{"key":"pntd.0009522.ref009","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijid.2019.07.015","article-title":"Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis","volume":"87","author":"KA Eberhardt","journal-title":"Int J Infect Dis"},{"key":"pntd.0009522.ref010","author":"H-Y Cheng","journal-title":"Evidence of ribavirin treatment for Lassa fever: a systematic review of published and unpublished studies"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T17:27:14Z","timestamp":1625765234000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009522"}},"subtitle":[],"editor":[{"given":"Remi N.","family":"Charrel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":10,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0009522","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]}}}